Description

Saralasin, also known as [Sar1, Ala8] Angiotensin II, is a synthetic octapeptide designed as a structural analog of angiotensin II. By binding to angiotensin II receptors, Saralasin acts as a competitive antagonist while also demonstrating partial agonist activity. Its dual functional profile has made it a widely studied molecule in the fields of cardiovascular physiology, hypertension, and renal function regulation.

One of the defining characteristics of Saralasin is its high affinity for angiotensin II receptor binding sites, with a Ki value of 0.32 nM for approximately 74% of the binding sites. This high receptor affinity underscores its ability to effectively block angiotensin II–mediated vasoconstriction while retaining measurable partial agonist activity, which provides valuable insights into receptor signaling dynamics.

As a GMP-manufactured research compound, Saralasin is produced to ensure high purity (98.71%) and consistency across research applications. It has been widely utilized in preclinical research exploring the renin–angiotensin–aldosterone system (RAAS), renovascular hypertension, and renin-dependent (angiotensinogenic) hypertension. Its ability to act as both a receptor blocker and weak agonist allows researchers to investigate the fine balance of angiotensin II receptor signaling in vascular and renal pathophysiology.

Saralasin is available in both bulk and smaller research quantities, supporting laboratories engaged in cardiovascular, renal, and hypertension-related investigations.

For laboratory research use only. Not for human consumption.

Product Specifications

Mechanism of Action & Research Applications

Saralasin exerts its primary pharmacological effect through competitive antagonism at angiotensin II receptors. By displacing angiotensin II from its binding sites, Saralasin prevents vasoconstrictive and hypertensive effects normally induced by angiotensin II. At the same time, its partial agonist activity allows researchers to investigate receptor activation thresholds and partial receptor signaling.

Key research applications of Saralasin include:

• Renovascular Hypertension Research – has been widely used as a diagnostic and investigative tool for renovascular hypertension. Its ability to block angiotensin II–induced responses makes it useful in distinguishing renin-dependent from non-renin-dependent forms of hypertension.

• Renin-Dependent Hypertension Studies – By antagonizing angiotensin II, Saralasin helps delineate the contribution of RAAS hyperactivity to hypertensive conditions.

• RAAS Physiology and Pathophysiology – is valuable for exploring the role of angiotensin II in cardiovascular regulation, renal perfusion, and systemic blood pressure control.

• Comparative Pharmacology – Its dual antagonist/partial agonist behavior provides a unique tool for studying receptor pharmacodynamics.

Development & Research Background

The development of Saralasin represents a critical milestone in the pharmacological investigation of the renin–angiotensin system. As one of the earliest angiotensin II analogs designed to act as a receptor antagonist, it provided researchers with unprecedented insights into the role of angiotensin II in blood pressure regulation.

In clinical research settings, Saralasin was once considered as a therapeutic candidate for hypertension, but its partial agonist activity limited its long-term therapeutic potential. However, its importance in research remains significant, as it paved the way for the development of more selective and clinically effective angiotensin receptor blockers (ARBs) such as losartan and valsartan.

Today, Saralasin continues to be utilized in laboratory research to explore renovascular hypertension, renin-dependent mechanisms, and receptor signaling modulation. Its role as both a research probe and a historical steppingstone in cardiovascular drug development underscores its continued relevance.

Side Effects

In research models, Saralasin has been reported to cause:

• Transient hypotension or hypertension (depending on dose and receptor context)

• Vascular reactivity changes

• Partial agonist responses complicating dose-response interpretation

• Potential renal perfusion effects

These observations are based on experimental and preclinical data. Side effects are provided for reference only in laboratory research contexts.

Disclaimer

is supplied strictly for laboratory research use only. It is not intended for human or veterinary use, nor for clinical, diagnostic, or therapeutic applications. All handling should follow appropriate laboratory safety protocols.

Keywords

 CAS 34273-10-4, Saralasin peptide, angiotensin II antagonist, RAAS research compound, renovascular hypertension research, renin-dependent hypertension research, cardiovascular research peptides, GMP Saralasin supplier